PT  - JOURNAL ARTICLE
AU  - IWASA, SATORU
AU  - NAKAJIMA, TAKAKO EGUCHI
AU  - NAGASHIMA, KENGO
AU  - HONMA, YOSHITAKA
AU  - KATO, KEN
AU  - HAMAGUCHI, TETSUYA
AU  - YAMADA, YASUHIDE
AU  - SHIMADA, YASUHIRO
TI  - Lack of Association of Proteinuria and Clinical Outcome in Patients Treated with Bevacizumab for Metastatic Colorectal Cancer
DP  - 2013 Jan 01
TA  - Anticancer Research
PG  - 309--316
VI  - 33
IP  - 1
4099  - http://ar.iiarjournals.org/content/33/1/309.short
4100  - http://ar.iiarjournals.org/content/33/1/309.full
SO  - Anticancer Res2013 Jan 01; 33
AB  - Background: Although bevacizumab-related hypertension has been reported as a predictive marker of therapy efficacy, an association between proteinuria and efficacy has not been reported. Patients and Methods: Eighty-two consecutive patients with metastatic colorectal cancer treated with bevacizumab as first-line treatment between July 2007 and April 2009 were examined. Results: Seventy-one patients were included in the analysis set. Proteinuria occurred in 29 patients: Grade 1 in 15 patients and grade 2 in 14 patients; no grade 3 or higher proteinuria was observed. The response rate did not increase with the severity of proteinuria (p=0.307). The median progression-free survival was 17.8 months in cases with grade 2 proteinuria, 16.0 months in those with grade 1 proteinuria, and 10.4 months in those with grade 0 proteinuria (p=0.030). In multivariate analysis with a time-dependent adjustment, there was no correlation between severity of proteinuria and survival. Conclusion: Bevacizumab-related proteinuria was not a predictive marker for patients with colorectal cancer treated with first-line bevacizumab.